Aerovate Therapeutics (AVTE) Stock Price, News & Analysis

Company Overview

Aerovate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops drugs that enhance the lives of patients with rare cardiopulmonary diseases in the United States. It focuses on advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension, which is in Phase 2b/Phase 3 trial. The company was incorporated in 2018 and is headquartered in Waltham, Massachusetts.

Key Stats

• Today's Range: $2.53 to $2.58
• 50-Day Range: $1.88 to $2.79
• 52-Week Range: $1.25 to $32.42
• Volume: 524,252 shs
• Average Volume: 618,118 shs
• Market Capitalization: $73.05 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $2.25
• Consensus Rating: Hold

Aerovate Therapeutics Stock Analysis - MarketRank™

Aerovate Therapeutics scored higher than 33% of companies evaluated by MarketBeat, and ranked 820th out of 970 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 1.0 / 5
• Analyst Rating: Hold

Consensus Rating

Aerovate Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no buy ratings, 6 hold ratings, and no sell ratings.

Amount of Analyst Coverage

Aerovate Therapeutics has received no research coverage in the past 90 days.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Aerovate Therapeutics are expected to grow in the coming year, from ($2.74) to ($0.88) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Aerovate Therapeutics is -0.85, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Aerovate Therapeutics is -0.85, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Aerovate Therapeutics has a P/B Ratio of 0.91. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

2.81% of the float of Aerovate Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Aerovate Therapeutics has a short interest ratio ("days to cover") of 0.7, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Aerovate Therapeutics has recently decreased by 17.32%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Aerovate Therapeutics does not currently pay a dividend.

Dividend Growth

Aerovate Therapeutics does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

2.81% of the float of Aerovate Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Aerovate Therapeutics has a short interest ratio ("days to cover") of 0.7, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Aerovate Therapeutics has recently decreased by 17.32%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 2.9 / 5
• News Sentiment: 1.19

News Sentiment

Aerovate Therapeutics has a news sentiment score of 1.19. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.55 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 12 news articles for Aerovate Therapeutics this week, compared to 2 articles on an average week.

MarketBeat Follows

Only 2 people have added Aerovate Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Aerovate Therapeutics insiders have not sold or bought any company stock.

Percentage Held by Insiders

24.90% of the stock of Aerovate Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.

AVTE Stock Analysis - Frequently Asked Questions

How have AVTE shares performed this year?

Aerovate Therapeutics' stock was trading at $22.63 on January 1st, 2024. Since then, AVTE shares have decreased by 88.8% and is now trading at $2.53.
View the best growth stocks for 2024 here.

How were Aerovate Therapeutics' earnings last quarter?

Aerovate Therapeutics, Inc. (NASDAQ:AVTE) announced its earnings results on Tuesday, November, 12th. The company reported ($0.56) EPS for the quarter, topping analysts' consensus estimates of ($0.59) by $0.03.

When did Aerovate Therapeutics IPO?

Aerovate Therapeutics (AVTE) raised $100 million in an IPO on Wednesday, June 30th 2021. The company issued 7,150,000 shares at $13.00-$15.00 per share.

Who are Aerovate Therapeutics' major shareholders?

Aerovate Therapeutics' top institutional investors include GSA Capital Partners LLP (1.43%), State Street Corp (1.27%), Geode Capital Management LLC (1.01%) and Verition Fund Management LLC (0.35%). Insiders that own company stock include David S Grayzel, Hunter Gillies, George A Eldridge, Ralph Niven, Benjamin T Dake, Marinus Verwijs and Timothy P Noyes.
View institutional ownership trends.

How do I buy shares of Aerovate Therapeutics?

Shares of AVTE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

What other stocks do shareholders of Aerovate Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Aerovate Therapeutics investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Netflix (NFLX), Palo Alto Networks (PANW), Tesla (TSLA) and JPMorgan Chase & Co. (JPM).

Company Calendar

• Last Earnings: 11/12/2024
• Today: 11/16/2024
• Fiscal Year End: 12/31/2024
• Next Earnings (Estimated): 3/24/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:AVTE
• CUSIP: N/A
• CIK: 1798749
• Web: aerovatetx.com
• Phone: 617-443-2400
• Fax: N/A
• Employees: 51
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $2.25
• High Stock Price Target: $3.00
• Low Stock Price Target: $2.00
• Potential Upside/Downside: -11.1%
• Consensus Rating: Hold
• Rating Score (0-4): 2.00
• Research Coverage: 6 Analysts

Profitability

• EPS (Most Recent Fiscal Year): ($2.99)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-75,520,000.00
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -90.19%
• Return on Assets: -77.47%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 8.78
• Quick Ratio: 6.51

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $2.79 per share
• Price / Book: 0.91

Miscellaneous

• Outstanding Shares: 28,875,000
• Free Float: 21,680,000
• Market Cap: $73.05 million
• Optionable: Optionable
• Beta: 1.00